Dermaliq Therapeutics

What Dermaliq Therapeutics does

Dermaliq Therapeutics, Inc. is a privately held, venture-backed specialty pharmaceutical company founded in 2021 as a spin-off from Novaliq GmbH and incorporated in Wilmington, Delaware, with research and development operations in Heidelberg, Germany. The company develops topical prescription drug therapies for dermatology indications using hyliQ®, a proprietary water-free carrier-molecule technology platform originally validated in ophthalmology where it underpins more than 15 global regulatory approvals and two FDA-approved drugs (Miebo® and Vevye®). Dermaliq is advancing three clinical-stage assets: DLQ01, a topical prostaglandin F2α analog in hyliQ® for androgenetic alopecia with positive Phase 1b/2a data; DLQ02, a topical calcineurin inhibitor repurposed for alopecia areata; and DLQ03, a topical antibiotic for wound healing and bacterial skin infections now also being extended into Epidermolysis Bullosa via a strategic collaboration with DEBRA Research announced in May 2025.

The company monetizes through eventual commercialization of prescription topical products and through strategic co-development and out-licensing partnerships, and is currently raising a Series B to fund later-stage clinical development. Its pipeline targets high-unmet-need indications where current topical options are limited — androgenetic alopecia (especially female pattern hair loss), alopecia areata, and the rare skin fragility disorder Epidermolysis Bullosa — with the central value proposition being follicle- and gland-targeted drug delivery enabled by hyliQ® that avoids irritating excipients and delivers superior bioavailability and cosmetic properties compared with conventional formulations.

The company is led by CEO and President Dr. Christian Roesky (former CEO of Novaliq and senior leader at Bausch + Lomb, Abbott, and Alcon), CFO and co-founder Dr. Oliver Schlüter (also CFO of Novaliq and former CFO of CureVac), and CSO and co-founder Dr. Betsy Hughes-Formella, with independent director Robert J. Moccia bringing specialty pharma commercialization experience from Strata Skin Sciences, Encore Dermatology, Precision Dermatology, and Medicis. Scientific and clinical credibility is supported by a Scientific Advisory Board that includes Prof. Rod Sinclair, Gordon Dow, Michael Kuligowski, R. Todd Plott, Xavier Yon, and Ralf Paus. As of the latest disclosures, Dermaliq operates with 1-10 employees and has raised USD 15 million in Series A funding led by 3E Bioventures Capital with participation from Beijing Whale Technology Corporation Ltd, plus a strategic investment from DEBRA Research in conjunction with the May 2025 EB collaboration.

Name

Dermaliq Therapeutics

Legal name

Dermaliq Therapeutics, Inc.

Website

https://dermaliq.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Dermaliq Therapeutics is a venture-backed clinical-stage pharmaceutical company developing topical dermatology therapies using its proprietary hyliQ® carrier-molecule delivery platform, targeting androgenetic alopecia, alopecia areata, wound healing, and Epidermolysis Bullosa patients.

Ownership category

akta.pro rank

Product category

Dermatology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

• Topical dermatology drugs
• Cutaneous drug delivery
• Clinical-stage pharmaceuticals
• Hair loss therapeutics
• Specialty dermatology biotech

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Sales: As a clinical-stage pharmaceutical company, Dermaliq plans to generate revenue through the commercialization of prescription topical drug therapies. The company is developing a pipeline of drug candidates targeting dermatology indications including androgenetic alopecia, alopecia areata, wound healing, and epidermolysis bullosa.
2. Strategic Partnerships and Licensing: Dermaliq is actively seeking strategic partners for co-development and licensing agreements. The company mentions seeking strategic partners and investors for Series B financing round to support continued development and potential out-licensing of pipeline assets.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Dermaliq Therapeutics is a clinical-stage specialty pharmaceutical company developing topical prescription drug candidates for dermatology using its proprietary hyliQ® water-free carrier technology. The pipeline comprises three assets: DLQ01 (prostaglandin F2α analog for androgenetic alopecia), DLQ02 (calcineurin inhibitor for alopecia areata), and DLQ03 (broad-spectrum antibiotic for wound healing and Epidermolysis Bullosa). The company is headquartered in Wilmington, Delaware, with R&D operations in Heidelberg, Germany.

Product overview

Dermaliq Therapeutics is a venture-backed US specialty pharmaceutical company with operations in Heidelberg, Germany, focused on dermatology. The company develops breakthrough topical therapies and medical skin care products based on hyliQ®, a proprietary enabling technology platform. The product portfolio consists of three clinical-stage drug candidates: DLQ01 (prostaglandin F2α analog for androgenetic alopecia), DLQ02 (calcineurin inhibitor for alopecia areata), and DLQ03 (wound healing/antibiotic candidate). The hyliQ technology platform enables targeted delivery of active ingredients into hair follicles and skin glands without requiring skin irritating excipients such as preservatives or penetration enhancers. The technology was initially developed for ophthalmology where it has achieved regulatory approvals including USA, Europe and China.

Differentiator

Problem solved

Functional benefit

Products and services

• DLQ01 Clinical-stage liquid topical formulation of a prostaglandin F2α analog delivered via hyliQ® technology for the treatment of androgenetic alopecia (male and female pattern hair loss). Designed to stimulate scalp hair growth by activating follicular stem cells and promoting transition from telogen (resting) to anagen (growth) phase; positioned as a non-gender-specific, non-hormonal topical therapy.
• DLQ02 Clinical-stage liquid topical calcineurin inhibitor using hyliQ® technology with anti-inflammatory and immunomodulating properties. Originally developed for plaque psoriasis, now being repositioned toward alopecia areata, offering a dual mode of action combining immunomodulation with hirsutism to promote additional hair growth.
• DLQ03 Clinical-stage broad-spectrum liquid antibiotic drug candidate using hyliQ® technology for accelerated wound healing and prevention of secondary skin infections, including burn wounds and post-aesthetic-procedure wounds; in collaboration with DEBRA Research, also being developed for Epidermolysis Bullosa.

Quantifiable outcome

• 83% of DLQ01 treated subjects showed a positive hair growth response with >500% relative hair count improvement vs vehicle
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• DEBRA ResearchcoreStrategic or Co-development Partner · 28 May 2025DEBRA Research and Dermaliq announced a strategic collaboration to develop topical treatments for Epidermolysis Bullosa (EB), focusing on wound healing, itch relief, and preventive therapies. The partnership leverages Dermaliq's hyliQ® technology for touchless drug delivery to fragile skin. DEBRA Research is a global nonprofit organization dedicated to advancing research and drug development for those affected by EB. As part of the agreement, DEBRA Research has also made a strategic investment in Dermaliq.
• Novaliq GmbHcoreStrategic or Co-development Partner · 18 January 2022Novaliq transferred and licensed Intellectual Property related to the field of dermatology to Dermaliq. Dermaliq was established as a spin-off from Novaliq to unlock value in medical dermatology by using Novaliq's transformative technology outside eye care. Novaliq developed the patent-protected hyliQ® technology platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Aclaris Therapeutics: Aclaris Therapeutics is a clinical-stage specialty pharmaceutical company developing innovative treatments for dermatological indications including androgenetic alopecia (ATI-1777) and immuno-inflammatory skin diseases, making it a directly comparable peer in dermatology drug development.
• Arcutis Biotherapeutics: Arcutis is a dermatology-focused pharmaceutical company developing topical treatments for plaque psoriasis, atopic dermatitis, and other skin conditions. It is a direct peer given its emphasis on topical formulations addressing underserved dermatology indications.
• Verrica Pharmaceuticals: Verrica is a clinical-stage dermatology company developing topical therapies for skin diseases, including molluscum contagiosum and condyloma. It is comparable in being a small, dermatology-focused pharma with topical delivery focus and pipeline-stage assets.
• Cassiopea: Cassiopea developed topical dermatology products including Winlevi (clascoterone) for acne and had an androgenetic alopecia program, making it a directly relevant peer in topical dermatology pharmaceuticals.
• Journey Medical Corporation: Journey Medical is a commercial-stage dermatology company marketing multiple prescription skincare products. It is comparable as a similarly-sized dermatology-focused pharmaceutical company targeting similar prescribing dermatologists.

Emerging players

• Follica: Follica is an emerging clinical-stage company developing novel treatments for hair loss, directly competing with Dermaliq's DLQ01 in the androgenetic alopecia space with a different mechanism (device-assisted follicular disruption).

Broad incumbents

• Ortho Dermatologics (Bausch Health): Ortho Dermatologics is the dermatology specialty division of Bausch Health and a broad incumbent player offering multiple prescription dermatology products, including hair loss treatments like minoxidil-based formulations, competing in Dermaliq's target market.
• Eli Lilly (Olumiant/baricitinib): Eli Lilly's baricitinib (Olumiant) received FDA approval for severe alopecia areata, making it a broad incumbent competitor to Dermaliq's DLQ02 in the alopecia areata space with a systemic oral JAK inhibitor.
• Pfizer (minoxidil franchise): Pfizer markets Rogaine (minoxidil), the incumbent topical hair loss treatment that DLQ01 is positioned to displace. It is a broad incumbent peer whose franchise revenue defines the addressable market opportunity for Dermaliq's lead asset.

Others

• Novaliq GmbH: Novaliq is the parent company that spun off Dermaliq and transferred the hyliQ®/EyeSol® technology IP. It is comparable as the originator of the underlying platform technology and developer of FDA-approved ophthalmology drugs (Miebo, Vevye) using the same carrier-molecule approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/dermaliq-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dermaliq Therapeutics